

Vitamin D receptors and hyperparathyroidism

To the editor — Carling and colleagues report that the frequency of the vitamin D₃ receptor (VDR) genotype *bb* in Caucasian patients with primary hyperparathyroidism (HPT) is higher than that in control subjects¹. They speculate that reduced VDR expression in parathyroid glands may impede adequate suppression by vitamin D₃ in subjects with the genotype *bb* and may contribute to parathyroid tumorigenesis in those subjects.

We have analyzed the frequency of *BsmI* and *Apal* polymorphism in intron 8 of the VDR gene, in 22 Japanese patients with HPT (46–80 years old) and generation-matched control subjects. Peripheral leukocyte DNA was amplified using the polymerase chain reaction (PCR) and the products digested with *BsmI* or *Apal* (ref. 2, 3). Genotype *bb* was found in 18 of the 22 patients with HPT (82%) and in 70 of the 92 control subjects (76%), revealing no significant difference. We found that the frequency of the *b* allele in Japanese subjects was much higher than that in Caucasians reported elsewhere^{4,5}. Genotypes *aa* and *Aa* (*Apal* polymorphism) were found in 13 and 8 of the 22 HPT patients, respectively. Those *aa* and *Aa* genotypes accounted for 31 and 31 of the 65 control subjects, respectively, and again, the frequency was not significantly different between HPT patients and controls. In Japan, the frequency of the *a* allele also seems higher than that in Caucasians³.

The prevalence of HPT in Japanese is about 1% (ref. 6), comparable to that in Caucasians. As calcium intake or duration of sun exposure could also influence vitamin D–parathyroid hormone axis, the effect of the VDR gene polymorphisms on parathyroid tumorigenesis may be a little different among various ethnic groups.

Finally, Howard and colleagues report that suppression of parathyroid hormone secretion by active vitamin D₃ administration is less effective in subjects with the genotype *BB* (ref. 7) and Dawson-Hughes and colleagues demonstrated decreased calcium absorption rates with a low-calcium diet, in the *BB* subjects⁸. These results conflict with the idea that decreased expression of VDR in the *bb* subjects may impair the effect of vitamin D₃. Further functional analy-

ses of the effects of VDR genotypes are necessary to clarify the exact relationship between VDR polymorphisms and HPT.

SHOICHIRO NAGASAKA¹, SAN-E ISHIKAWA¹, HANA MATOBA², KEN KUBOTA², TORU MURAKAMI² & TOSHIKAZU SAITO¹

¹Division of Endocrinology and Metabolism
Department of Medicine, Jichi Medical School
3311-1 Yakushiji, Minamikawachi
Tochigi 329-04, Japan

²Department of Medicine
Tokyo Metropolitan Komagome Hospital
Tokyo 113, Japan

1. Carling, T. *et al.* Vitamin D receptor genotypes in primary hyperparathyroidism. *Nature Med.* **1**, 1309–1311 (1995).

2. Morrison, N.A. *et al.* Prediction of bone density from vitamin D receptor alleles. *Nature* **367**, 284–287 (1994).
3. Riggs, B.L. *et al.* The contribution of vitamin D receptor gene alleles to the determination of bone mineral density in normal and osteoporotic women. *J. Bone Miner. Res.* **10**, 991–996 (1995).
4. Yamagata, Z. *et al.* Vitamin D receptor gene polymorphism and bone mineral density in healthy Japanese women. *Lancet* **344**, 1027 (1994).
5. Matsuyama, T. *et al.* Vitamin D receptor genotypes and bone mineral density. *Lancet* **345**, 1238–1239 (1995).
6. Shishiba, Y. Screening of primary hyperparathyroidism. *J. Jpn. Soc. Intern. Med.* **82**, 1928–1931 (1993).
7. Howard, G. *et al.* Genetic influences on bone density: Physiological correlates of vitamin D receptor gene alleles in premenopausal women. *J. Clin. Endocrinol. Metab.* **80**, 2800–2805 (1995).
8. Dawson-Hughes, B. *et al.* Calcium absorption on high and low calcium intakes in relation to vitamin D receptor genotype. *J. Clin. Endocrinol. Metab.* **80**, 3657–3661 (1995).

The greatest threat of all

To the editor — Your editorial (*Nature Medicine* **1**, 1221; 1995) points to 29 new or reemerging diseases during the past two decades and the international efforts to establish a global information infrastructure and global alert network. Undoubtedly, studies of the physiology, genetics and pathogenesis of these microbes should be initiated and pursued vigorously. However, it is also essential that the potential impact of global climate and environmental changes is taken seriously.

Even modest temperature changes can influence the distribution and abundance of vectors and intermediate hosts¹, and recent events have demonstrated that the performance of labile viral vaccines and other therapeutics can be suboptimal in developing countries² where refrigeration facilities may be poor and temperature fluctuations extreme. The potential impact of global climate

changes on vaccine potency in the field could be minimized by first assessing the detailed environmental characteristics of various locations and then selecting products that can withstand these conditions. The development and availability of fully stabilized products would also be invaluable.

Basic laboratory research alone fails to take account of the influence the environment may have on our attempts to better treat and manage the threat of emerging diseases.

SUBHASH C. ARYA

Center for Logistical Research and Innovation
M-122, Greater Kailash-II
New Delhi, India 110048

1. Reeves, W.C. *et al.* Potential effect of global warming on mosquito-borne arboviruses. *J. Med. Entomol.* **31**, 323–332 (1995).
2. Arya, S.C. Immunotechnological products in adverse global environments. *Immunotechnology* **1**, 169–173 (1995).

LETTERS TO THE EDITOR

Nature Medicine encourages brief letters (fewer than 500 words) on topics that are likely to be of wide interest within the biomedical research community. Contributions presenting a novel perspective on a topical issue and of a relatively nontechnical nature are favored, although letters presenting new but preliminary data of exceptional interest are occasionally published. Letters should be addressed to *Nature Medicine*, 545 National Press Building, 529 14th Street NW, Washington, DC 20045, USA, or sent by fax (202.626.0970) or by e-mail (medicine@naturedc.com).